Contineum Therapeutics, Inc. Class A Common Stock
CTNM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $43 | $21 | $22 | $22 |
| Short-Term Investments | $140 | $155 | $168 | $183 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $3 | $1 | $1 | $2 |
| Total Curr. Assets | $185 | $177 | $192 | $206 |
| Property Plant & Equip (Net) | $6 | $6 | $6 | $6 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $0 |
| Total NC Assets | $6 | $6 | $6 | $6 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $191 | $183 | $198 | $213 |
| Liabilities | – | – | – | – |
| Payables | $1 | $2 | $4 | $2 |
| Short-Term Debt | $1 | $1 | $1 | $1 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $4 | $4 | $4 | $7 |
| Total Curr. Liab. | $6 | $7 | $9 | $10 |
| LT Debt | $4 | $4 | $5 | $5 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $4 | $4 | $5 | $5 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $6 | $6 | $6 |
| Total Liabilities | $10 | $11 | $13 | $15 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$162 | -$149 | -$133 | -$117 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $342 | $321 | $318 | $315 |
| Total Equity | $180 | $171 | $185 | $198 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $191 | $183 | $198 | $213 |
| Net Debt | -$37 | -$15 | -$16 | -$16 |